Edrecolomab
Edrecolomab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target epithelial cell adhesion molecule.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| choline c 11 | New Drug Application | 2025-12-26 |
| zyrexal | unapproved drug other | 2020-02-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
822 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Discoid lupus erythematosus | D008179 | — | L93.0 | 1 | — | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Edrecolomab |
| INN | edrecolomab |
| Description | Edrecolomab (mouse mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108955 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13375 |
| UNII ID | 0KYI9U9FSJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EPCAM
EPCAM
Organism
Homo sapiens
Gene name
EPCAM
Gene synonyms
GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1
NCBI Gene ID
Protein name
epithelial cell adhesion molecule
Protein synonyms
Adenocarcinoma-associated antigen, CD326, Cell surface glycoprotein Trop-1, EGP, EGP314, Epithelial cell surface antigen, Epithelial glycoprotein, Epithelial glycoprotein 314, hEGP314, human epithelial glycoprotein-2, KS 1/4 antigen, KSA, Major gastrointestinal tumor-associated protein GA733-2, membrane component, chromosome 4, surface marker (35kD glycoprotein), trophoblast cell surface antigen 1, Tumor-associated calcium signal transducer 1
Uniprot ID
Mouse ortholog
Epcam (17075)
epithelial cell adhesion molecule (Q99JW5)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 311,221 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,046 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use